Significance of pretreatment cardiovascular morbidity as a risk factor during treatment with parenteral oestrogen or combined androgen deprivation of 915 patients with metastasized prostate cancer: evaluation of cardiovascular events in a randomized trial
Research output: Contribution to journal › Journal article › Research › peer-review
This study aimed to evaluate prognostic risk factors for cardiovascular events during treatment of metastatic prostate cancer patients with high-dose parenteral polyoestradiol phosphate (PEP, Estradurin®) or combined androgen deprivation (CAD) with special emphasis on pretreatment cardiovascular disease.
| Original language | English |
|---|---|
| Journal | Scandinavian Journal of Urology and Nephrology |
| Volume | 45 |
| Issue number | 5 |
| Pages (from-to) | 346-53 |
| Number of pages | 8 |
| ISSN | 0036-5599 |
| DOIs | |
| Publication status | Published - 2011 |
ID: 40162064